newheader.jpg
 


Conference Menu

Overview
Day 1
Day 2
Register
Download PDF
Hotel & Travel
Poster
Sponsor
Press Pass
Request Brochure
Send to a Colleague
 
Lead Sponsoring Publications
 
Sponsoring Publications

 

Web Partners:

 
 
 

Register by August 25th and receive discounted rate!

Day Two


Wednesday, October 4

7:30 Morning Coffee (Breakfast Workshop Sponsorship Available)

8:05 Chairperson’s Remarks
Dr. Alex D. Kanarek, President, Bio-Development Consulting Services

   Audits

8:10 How to Conduct Yourself During an Agency Inspection
Mr. Jim Carignan, RQAP-GLP, Chiron Corp.
What happens when you hear to the feared words, “The agency is here to conduct a formal inspection?” What should you do? What should you say? What do you give them? What can they take? Those are questions that haunt most of us who work in a regulated environment. Prior experience is no guarantee. Many people who have experienced an inspection are still not sure of what is truly appropriate to say or do. For the inspection novice, this session will provide an overview of what typically happens during an inspection. For the more experienced, it will provide suggestions on how you, your management and staff should conduct yourselves during, what for most of us, is an extremely tense situation. It won't turn a sow's ear into a silk purse, but properly applied, the suggestions will maximize your efforts and increase the likelihood of a successful inspection result.

8:45 FDA 483 Warning Letters 
Mr. Patrick DeVillier, Director, Compliance, A.P. Pharma, Inc.
In coming to understand FDA 483s and the potential for subseqeunt warning letters we will begin with an overview of FDA inspections and related regulations. Our discussions will include preparing for an inspection and the hosting of an FDA inspection. We will cover and assess the nature of the most common types of observations documented by field inspectors on Form FDA 483. Having received a 483, we will discuss a pragmatic approach to providing effective responses in a timely manner. 

9:20 CAPA Compliant Root Cause Investigation and Documentation
Mr. John Ager, Consultant, Kepner Tregoe Inc.
Learn to conduct robust root cause analyses on unexpected deviations using lab, manufacturing and quality data to clearly document investigations to prevent FDA 483s, inspection findings, and warning letters. This presentation will present a systematic four step process to find root cause. First, describe the problem with a clear, complete problem statement and specification. Second, identify possible causes using both knowledge and experience as well as distinctions and changes. Third, evaluate possible causes by testing them against the problem specification to determine the most probable cause. Finally, confirm the true cause by verifying assumptions, observing, experimenting, fixing, and monitoring.

9:55 Networking Coffee Break, Poster Viewing

10:30 Roundtable Discussions: Getting Close and Personal

Several topics will be discussed at multiple tables (two tables per topic). Moderators will rotate between tables, allowing attendees to discuss all topics. Great opportunity to discuss individual questions and experiences and network with your colleagues. 

Topic 1: FDA 483 Warning Letters
Moderators:
Mr. Patrick DeVillier, Director, Compliance, A.P. Pharma, Inc.
Mr. Wade Speir, Pharmaceutical Practice Leader, Kepner-Tregoe, Inc.

Topics:
• How serious is a Warning Letter? 
• Does it automatically follow a 483? 
• Does it have legal status?
• How do we avoid getting one? 
• What do you do when you get one?

Topic 2 : How to Audit Effectively
Moderators:

Mr. Jim Carignan, RQAP-GLP, Chiron Corp.
Dr. Alex D. Kanarek, President, Bio-Development Consulting Services

Topics:
• What is an effective audit?
• When should you audit?
• How often should you audit a study?
• Who should do the audit?
• What are the main points to observe?
• What are the warning signs that an audit may uncover?
• What do you do with the audit results?
• What is an effective audit report?

Topic 3: In House vs. Outsourcing 
Moderators:

Mr. Joe Czwiertniewicz, Principal, Quality and Regulatory Compliance
Ms. Linda Palagi-Lynn, RQAP-GLP, LPL Quality Services

Topics: 
• Qualification of CROs (Contract Research Organizations) 
• The reporting process – making sure all the data generated gets reported 
• QAUs for multi-site studies – ensuring everything is covered

12:00 Lunch on Your Own (Luncheon Workshop Sponsorship Available)

1:15 Chairperson’s Remarks

   Documentation and Data Management

1:20 Validating GLP Computer Systems
Mr. James Joy, Chief Technology Officer, Compliant Systems Integration, Inc.
Computer software and hardware system validation is required for Good Laboratory Practices compliance by both US and international regulatory agencies. Industry best practices recommend a risk-based approach to system life cycle development and for implementing custom, configurable, commercial off-the-shelf software systems or hosted applications. Each development process step including analysis, user/system requirements gathering, design, development, testing, implementation, change control and system retirement is critical for a compliant quality system. Documentation at each stage insures adequate validation for regulatory inspections. Combining FDA regulations with their initiative for a risk-based approach to computer system compliance addresses user and regulatory requirements.

1:55 Implementing LIMS into the Lab
Ms. Brigitte Staecker, Thermo Electron (invited)

2:30 Open, Application Driven LIMS for Proteomic Discovery
Mr. James DeGreef, Vice President, Product Management, GenoLogics Life Sciences Software, Inc.
In our presentation, we spotlight a recent system implementation at the Scripps Florida Institute that utilizes a hydrogen-deuterium exchange (HDX) experiment approach towards pharmacoproteomics efforts. Scripps integrated bioinformatics analysis tools developed in-house, with open source tools provided by the Institute for Systems Biology, and combined these tools with the end-to-end workflow and data management of GenoLogics’ Proteus to provide a complete information management solution for analysis from foundational data acquisition to analysis and visualization. The open architecture of Proteus allowed for ease of integration with “best of breed:” software tools and instrumentation.

3:05 Networking Refreshment Break and Poster Viewing

   Outsourcing and Multiple Studies

3:30 Sponsors, Responsibilities, and Multiple Site Studies 
Mr. Joe Czwiertniewicz, Principal, Quality and Regulatory Compliance
GLP studies often involve portions of studies being performed at multiplelocations. Defining the roles, responsibilities, expectations and deadlines are key to successful outcomes. Prequalification auditing, study monitoring and effective communications are essential to keeping studies on schedule.

4:25 The Regulatory Impact of Outsourcing
Mr. Scott Cook, QA Manager, Charles River Labs

5:15 End of Conference


For more information, please contact:
Margit Eder, Ph.D.,
Conference Director, Cambridge Healthtech Institute
Phone: 781-972-5478 E-mail: meder@healthtech.com  

For exhibits and sponsorship information, please contact:
David Karp at 781-972-5483 or dkarp@healthtech.com

foot.jpg


Cambridge Healthtech Institute| Beyond Genome | Bio-IT World | Biomarker World Congress | Cambridge Health Associates | Discovery On Target |
Health-IT World
| Bio-IT World Conference & Expo  | Molecular Medicine Tri-Conference | PEGS| PepTalk | Pharma DD
World Pharmaceutical Congress |

Your  Life Science Network

Cambridge Healthtech Institute  |  250 First Avenue  |  Suite 300   |   Needham,  MA  02494
Phone: 781-972-5400  |   Fax: 781-972-5425
chi@healthtech.com